title: [Markers of effectiveness of preoperative taxane-based chemotherapy for locally advanced breast cancer].
abstract: The absolute sensitivity signs of breast cancer to the drug have not yet been developed. Data from clinical trials on the study of experimental laboratory predictive markers of chemosensitivity: TOP2alpha (topoisomerase 2-alpha), beta-tubulin (subunit of dimeric protein tubulin), and BRCA1 (breast cancer 1) are contradictory and not numerous. Analysis of the results by the end of the clinical trial will allow examining the correlation between the effectiveness of preoperative taxane-chemotherapy and the level of experimental and standard molecular markets that is important for development of algorithm of treatment tactics for patients with locally advanced breast cancer.
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Semiglazova
authors.forename: V V
authors.initials: VV
authors.lastname: Klimenko
authors.forename: L V
authors.initials: LV
authors.lastname: Filatova
authors.forename: V A
authors.initials: VA
authors.lastname: Chubenko
authors.forename: P V
authors.initials: PV
authors.lastname: Krivorot'ko
authors.forename: V G
authors.initials: VG
authors.lastname: Ivanov
authors.forename: E A
authors.initials: EA
authors.lastname: Turkevich
authors.forename: A O
authors.initials: AO
authors.lastname: Ivantsov
authors.forename: S N
authors.initials: SN
authors.lastname: Novikov
authors.forename: V V
authors.initials: VV
authors.lastname: Semiglazov
authors.forename: R V
authors.initials: RV
authors.lastname: Donskikh
authors.forename: F V
authors.initials: FV
authors.lastname: Moiseenko
authors.forename: E A
authors.initials: EA
authors.lastname: Bus'ko
authors.forename: Zh V
authors.initials: ZhV
authors.lastname: Briantseva
authors.forename: M A
authors.initials: MA
authors.lastname: Osipov
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovish
authors.forename: E N
authors.initials: EN
authors.lastname: Imianitov
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D004250:DNA Topoisomerases, Type II / Q000032:analysis; D004268:DNA-Binding Proteins / Q000032:analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D057234:Preoperative Period; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D014404:Tubulin / Q000032:analysis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D043823:Taxoids; D014404:Tubulin; D004250:DNA Topoisomerases, Type II